Recurrent Squamous Cell Lung Carcinoma Active Not Recruiting Phase 2 / 3 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Active Not Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02154490Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerTreatment